Phase II study of the combination of Oxaliplatin and 5FU(mFOLFOX6) in patients with unresectable advanced/recurrent small intestinal cancer

ABSTRACT: Interventions: mFOLFOX6 Primary outcome(s): Progression-Free rate Study Design: Single arm Non-randomized

DISEASE(S): Unresectable Advanced/recurrent Small Intestinal Cancer

PROVIDER: 2618269 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR